Global Rare Cell Isolation Market Revenue Grows at a CAGR of 10.37%

Introduction

Straits Research released its highly anticipated report, “Global Rare Cell Isolation Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 2.40 billion in 2025 and is anticipated to grow to USD 5.96 billion by 2034, growing at a CAGR of 10.37% from 2026-2034.

Market Dynamics

The growth of the rare cell isolation market is primarily driven by the rising adoption of liquid biopsy and precision oncology approaches that rely on the detection and characterization of circulating tumor cells for early cancer diagnosis and treatment monitoring. Continuous funding in cell-based research and the expanding application of rare cell enrichment in immunology, regenerative medicine, and prenatal diagnostics further accelerate market growth. However, the high operational cost of advanced isolation instruments and the technical complexity associated with maintaining cell viability and purity limit widespread adoption among smaller laboratories and academic centers. Despite these challenges, the market presents strong opportunities through the diversification of rare cell isolation applications beyond oncology, particularly in cardiovascular and autoimmune disease research, where the isolation of circulating endothelial and rare immune cells supports novel biomarker discovery and personalized therapeutic development.

Market Highlights

• Product: Based on Product, the instruments segment is projected to record the fastest growth of 11.12% during the forecast period.
• Type: Based on Type, the stem cells segment dominates the market, accounting for the largest revenue share of 41.27% in 2025.
• Technology: Based on Technology, the microfluidics-based techniques segment leads the market in 2025 with a revenue share of 35.23%.
• Regional Insights: North America dominated the market with more than 47% of market share in 2025, driven by the strong presence of biotechnology and pharmaceutical companies, expanding investment in cancer diagnostics, and increasing adoption of advanced cell isolation systems in research and clinical laboratories.

Competitive Players

1. SGS Société Générale de Surveillance SA
2. Bio-Rad Laboratories, Inc.
3. Miltenyi Biotec
4. Thermo Fisher Scientific Inc.
5. DH Life Sciences, LLC. 
6. QIAGEN
7. Bio-Techne
8. STEMCELL Technologies
9. Cellenion SASU
10. RareCyte, Inc.
11. Illumina, Inc.
12. Akadeum Life Sciences
13. Applied Cells, Inc.
14. Beckman Coulter, Inc. 
15. BD
16. BioFluidica
17. Merck
18. Merck KGaA
19. SEED Biosciences SA 
20. Rarecells, Inc.
21. Others

Recent Developments

January 2025: SGS Société Générale de Surveillance SA launched Germany’s first commercial cell-sorting service using fluorescence-activated cell sorting (FACS) to support biopharma, cell & gene therapies.

Segmentation

1. By Product (2026-2034)
   1. Reagent & Kits
   2. Instrument
2. By Type (2026-2034)
   1. Circulating Tumor Cells
   2. Stem Cells
   3. Fetal Cells
   4. Rare Immune Cells
   5. Circulating Endothelial Cells
   6. Others
3. By Technology (2026-2034)
   1. Magnetic Bead Separation
   2. Fluorescence-Activated Cell Sorting
   3. Microfluidics-based techniques